Skip to main content
OpenTrials
Completed

NCT Number: NCT03972098

Uromodulin in Rheumatoid Arthritis

The aim of the present study was to evaluate the levels of uromodulin in rheumatoid arthritis (RA) and to investigate whether it was correlated with baseline clinical characteristics. In addition CKD epi,MDRD,urine microalbuminuria,pH,serum urea, creatinine,CRP (C-Reactive protein) were measured.The participants consist of ; %68 patients,% 32 control group.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Istanbul saglık Bilimleri Universty Gaziosmanpaşa Egitim ve Araştırma Hastanesi

Istanbul, Turkey (Türkiye)

About this study

Uromodulin, also known as Tamm-Horsfall protein, is a protein abundantly excreted in the urine in healthy individuals. It is synthesized in the thick ascending limb of Henle (TALH) and the early distal convoluted tubule. Its biologic function is still obscure; however, some experimental studies indicated that it might serve as an important urinary defense factor against bacterial colonization and stone formation.

There are controversial publications on the frequencies of urinary tract infections and nephrolithiasis in patients with mutations of uromodulin gene. Deposition of mutated uromodulin in the urinary system may lead to tubular cell dysfunction and apoptosis. These alterations may subsequently cause tubular atrophy and interstitial fibrosis . Moreover, the release of abnormal uromodulin after apoptosis through basolateral secretion may elicit an immune response which may give rise to an immune-mediated tubulointerstitial nephritis .

Uromodulin can activate the other components of the immune system and may modulate the inflammatory and immune responses through different mechanisms .

Experimental studies yielded that uromodulin negative mice displayed splenomegaly with infiltration of white pulp by macrophages and increased levels of TNF-α and interleukin-1 . Rheumatoid arthritis is a systemic autoimmune condition that may eventually result in the joint damage, disability and premature mortality.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients who diagnosed of rheumatoid arthritis as criteria of ACR/EULAR 2010.
  • All patients age range is 18-80 years.

Exclusion criteria

  • Renal failure
  • Hepatic insufficiency
  • Diabetes mellitus
  • Other collagen vascular diseases,
  • History of smoking and consumption of alcohol

Treatment and study plan

Primary outcomes

  1. Patients with rheumatoid arthritis

    Time frame: 1 day

    The diagnosis of RA was based on the criteria the American College of Rheumatology and European League Against Rheumatism (ACR/EULAR) in 2010.

    Patients selected

    • have at least 1 joint with definite clinical synovitis (swelling)
    • with the synovitis not better explained by another disease Classification criteria for RA (score-based algorithm: add score of categories A-D; a score of >6/10 is needed for classification of a patient as having definite RA)
  2. A.joint involvement

    Time frame: 1 day

    1 large joint (score 0) 2-10 large joints (score 1) 1-3 small joints (with or without involvement of large joints)#(score2) 4-10 small joints (with or without involvement of large joints)(score 3) 10 joints (at least 1 small joint) (score 5)

  3. B.Serology (at least 1 test result is needed for classification)

    Time frame: 1 day

    Negative RF and negative ACPA (Score 0) Low-positive RF or low-positive ACPA( anticitrullinated protein antibody) (score 2) High-positive RF(rheumatoid factor) or high-positive ACPA (score 3)

  4. C.Acute-phase reactants (at least 1 test result is needed for classification)

    Time frame: 1 day

    Normal CRP (C-reactive protein and normal) and normal ESR (erythrocyte sedimentation rate) (score 0) Abnormal CRP or abnormal ESR (score1)

  5. D.Duration of symptoms

    Time frame: 1 day

    <6 weeks (score 0) >6 weeks (score 1)

  6. Uromodulin measure

    Time frame: 1 day

    First urine sample taken in the morning

Secondary outcomes

  1. CKD-EPI (Chronic Kidney Disease Epidemiology Colloboration)

    Time frame: 1 day

    For estimating the glomerular filtration rate

  2. MDRD (Modification of Diet in Renal Disease)

    Time frame: 1 day

    For estimating the glomerular filtration rate

  3. Urea measure

    Time frame: 1 day

    Fasting blood samples taken in the morning

  4. Creatinine measure

    Time frame: 1 day

    Fasting blood samples taken in the morning

  5. Sedimantation measure

    Time frame: 1 day

    Fasting blood samples taken in the morning

  6. pH measure

    Time frame: 1 day

    First urine sample taken in the morning

  7. Microalbuminuria measure

    Time frame: 1 day

    First urine sample taken in the morning

Sponsors and collaborators

Lead sponsor

neval aksoy

Other

Registry information

Official study title

Uromodulin Levels in Rheumatoid Arthritis

Important dates

Study start
2017
Primary completion
2018
Study completion
2018
First posted
Jun 3, 2019
Registry last updated
Jun 3, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.